Myeloid Neoplasm with Histiocytosis and Spleen Tyrosine Kinase Fusion Responds to Fostamatinib
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Zeitlmann L, Knorr T, Knoll M, Romeo C, Sirim P, Kolanus W
. T cell activation induced by novel gain-of-function mutants of Syk and ZAP-70. J Biol Chem. 1998; 273(25):15445-52.
DOI: 10.1074/jbc.273.25.15445.
View
2.
Sada K, Zhang J, Siraganian R
. Point mutation of a tyrosine in the linker region of Syk results in a gain of function. J Immunol. 1999; 164(1):338-44.
DOI: 10.4049/jimmunol.164.1.338.
View
3.
Crowley H, Georgantzoglou N, Tse J, Williams E, Mata D, Martin S
. Expanding Our Knowledge of Molecular Pathogenesis in Histiocytoses: Solitary Soft Tissue Histiocytomas in Children With a Novel CLTC::SYK Fusion. Am J Surg Pathol. 2023; 47(10):1108-1115.
DOI: 10.1097/PAS.0000000000002102.
View
4.
Bussel J, Arnold D, Grossbard E, Mayer J, Trelinski J, Homenda W
. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018; 93(7):921-930.
PMC: 6055608.
DOI: 10.1002/ajh.25125.
View
5.
Mahmoodi M, Swami V, Besa E, Punnett H
. A second case of myelodysplastic syndrome with t(9;12)(q22;p12). Cancer Genet Cytogenet. 2005; 157(2):187-8.
DOI: 10.1016/j.cancergencyto.2004.08.002.
View